Leucinyl-arginyl-tryptophan (LRW) is a new peptide inhibitor of the angiotensin converting enzyme (ACE) that was previously predicted through quantitative structure-activity relationship modeling. LRW inhibited ACE activity in a competitive manner with a higher K m value in the presence of the peptide, and the in vitro formation of angiotensin II by ACE was significantly reduced in the presence of LRW up to 60 min of incubation time.
The angiotensin I-converting enzyme (ACE) (EC 3.4.15.1) is a zinc metalloprotease and a key enzyme that regulates various physiological functions through the renin-angiotensin-aldosterone system.
1) The predominant physiological function of ACE is in cardiovascular homeostasis through cleavage of the C-terminal dipeptide from angiotensin I to produce the potent vasoconstrictor, angiotensin II.
2) ACE also inactivates the vasodilator, bradykinin, by the sequential cleavage of two C-terminal dipeptides.
3) Therefore, ACE is a major target for cardiovascular therapy, and ACE inhibitors are widely used to treat cardiovascular diseases including hypertension, heart failure, coronary artery disease, and kidney failure. 1) Quantitative structure-activity relationship (QSAR) modeling of known ACE-inhibitory peptides has enabled us to predict and validate some new potentially active peptides, including the highly potent and novel tripeptide of leucyl-arginyltryptophan (LRW). 4) LRW is found within the primary structure of legumin A2 (f 377-379) and legumin A (f 374-376) of garden pea (Pisum sativum) seeds. Therefore, it will be possible in the future to design proteolytic and fractionation methods that will release and concentrate LRW from garden pea seeds so that the product can be used in the formulation of therapeutic foods. However, it is necessary to determine the ACEinhibitory properties and potential gastrointestinal (GI) stability of LRW prior to developing a comprehensive method to isolate the peptide from pea proteins. The aim of the present work was therefore to study the kinetics for the ACE inhibition of a synthetic version of LRW.
LRW was synthesized by Genscript Corporation (Piscatway, NJ, USA). The purity (98.4%) of the peptide was measured by HPLC, and its structure was verified by mass spectrometry (Genscript Corporation). Purified rabbit lung ACE, pepsin (from porcine stomach mucosa), pancreatin (from porcine pancreas), hippuryl-histidyl-leucine (HHL), hippuric acid (HA), synthetic human angiotensin I (Ang I) and angiotensin II (Ang II) were purchased from Sigma (St. Louis, MO, USA).
ACE inhibitory activity was determined by the spectrophotometric method of Cushman and Cheung.
5)
The reaction volume of 175 ml contained 2.5 mU of ACE, 5 mM of HHL, and a varied LRW concentration all in a 100 mM borate buffer that contained 300 mM NaCl at pH 8.3. The IC 50 value is defined as the concentration of LRW that was required to reduce ACE activity by 50% and was calculated by the non-linear regression method. The type of inhibition was determined by using a Lineweaver-Burk plot, 6) and K i was calculated as the X-axis intercept from a plot of the slopes of the Lineweaver-Burk lines against the peptide concentration. The HPLC method of Fruitier-Arnaudin et al. 7) was adapted to determine the rate of conversion of Ang I to Ang II by ACE at 37 C. Except for the replacement of HHL by Ang I (45 mM), the same assay components already indicated were used. However, for a time-course study, the reaction mixture was incubated for up to 120 min, and aliquots were taken at various times; the reaction was stopped by removing an aliquot and placing it in a boiling water bath for 5 min. After filtration through a 0.2-mm membrane, the aliquot of the incubation mixture was subjected to an HPLC analysis in a 5-mm Symmetry Ò C 18 column. Note incubation mixture (50 ml each) was injected and eluted with a linear gradient (15-35%) of acetonitrile in water (containing 0.1% TFA) over 20 min at a flow rate of 1.0 ml/min; the eluate was monitored at 210 nm. The concentration of Ang II was calculated from a standard curve prepared by using commercial Ang II. Each analysis was performed in duplicate and Student's t-test was carried out by the SAS computer software package (version 9.1; Cary, NC, USA) to determine the difference between two treatments. Significant difference was taken at p < 0:05. Figure 1 shows the dose-dependent ACE inhibition of LRW with up to an 80% decrease in enzyme activity obtained at a peptide concentration of about 0.95 mM. An IC 50 value of 0.15 mM was obtained, this being comparable to the value of 0.23 mM that has previously been reported. 4) Within our database of 168 dipeptides and 140 tripeptides that had been collected from published sources, 4) the most potent peptides (low IC 50 values) were IKW (0.21 mM) and LKP (0.32 mM), 8) LRP (0.27 mM), 9) MRW (0.60 mM), 10) and IVY (0.48 mM). 11) Of the long-chain peptides, FFGRCVSP (0.40 mM) and FKGRYYP (0.55 mM), 8) LRIPVA (0.38 mM), 10) VFPS (0.46 mM), 11) PTHIAW (0.39 mM), 12) and GHKIATFQER (0.40 mM) 13) have been reported to be very potent. The IC 50 values of the well-known milk tripeptides, VPP and IPP, are 5 and 9 mM, respectively while the casein C12 peptide of FFVAPFPEVFGK has been reported to have an IC 50 value of 77 mM.
14) Our present results show that the IC 50 value of LRW was comparable or even lower than most of the previously reported food proteinderived ACE-inhibitory peptides. LRW was also more potent than most venom ACE inhibitory peptides, with the exception of BPP 5a (Pyr-KWAP, IC 50 ¼ 0:06 mM).
15) However, LRW was much less potent than Captopril (IC 50 , 0.007 mM), which is a synthetic ACE inhibitor that is currently used as an antihypertensive drug. 16) Earlier structure and activity studies with synthetic venom peptide analogs have indicated that the optimal carboxy-terminal amino acid sequence of an inhibitor or substrate for binding to the enzyme was FAP, with an IC 50 value of 1.4 mM, 17) which is higher (less potent) than the value obtained for LRW in this work.
Lineweaver-Burk plots of ACE with or without LRW (at two LRW concentrations of 0.41 and 1.65 mM) are shown in Fig. 2 . The results indicate that LRW acted as a competitive inhibitor with respect to HHL as a substrate, which means that LRW competed with the substrate for the active site of ACE. The calculated K m value of ACE was 1.97 mM for HHL in the absence of LRW, which is close to the previously reported values of 1.34 mM 18) and 2.6 mM. 5) In the presence of an LRW concentration of 0.41 or 1.65 mM, the calculated K m 0 values were 3.19 and 5.85 mM for HHL, respectively. The calculated K i value was 0.75 mM, which is similar to the value of 0.74 mM that has been reported for a synthetic version of the venom decapeptide, Pyr-NWPHPQIPP. 14) However, the tuna-derived octapeptide, PTHIKWGD, a non-competitive inhibitor of ACE has been reported to have K i value of 1.7 mM, 19) which is higher than the 0.75 mM value for LRW. The inhibition constant represents the dissociation for the enzymeinhibitor complex; therefore, the lower the value, the greater the affinity of the inhibitor for the enzyme. Figure 3 shows the time-course formation of Ang II in the absence and presence of LRW. In the absence of LRW, the formation of Ang II increased quickly up to 60 min, and then slightly up to 120 min. In the presence of LRW, however, the formation of Ang II increased slowly in the first 60 min, but then increased to the same level as that for the uninhibited reaction after 120 min. Compared with the control (without LRW addition) at the same incubation time, the addition of LRW led to a significant decrease (p < 0:05) in the formation of Ang II from 5 min to 60 min. However, at 120 min, there was no significant difference (p > 0:05) between the amount of Ang II formed in the presence and absence of LRW (Fig. 3) . The result is consistent with the fact that the maximum rate is similar for inhibited and noninhibited reactions during competitive enzyme inhibition as shown in Fig. 2 . In the classic renin-angiotensin system, ACE is considered to be the major enzyme responsible for Ang II generation and consequently in the regulation of blood pressure. Our current in vitro results confirm that LRW inhibited the ACE-catalyzed formation of Ang II from Ang I, indicating a potential role of LRW in blood pressure regulation. However, the relationship between Ang II reduction by LRW and the in vivo hypotensive effect needs to be confirmed in an animal model.
In conclusion, LRW was found to be an effective ACE-inhibitory peptide with the ability to reduce the in vitro release of angiotensin II up to 1 hr of reaction time. Future work will involve the design of proteolytic and purification protocols that will release and isolate LRW from pea proteins; the food-derived form would be cheaper than the synthetic version. The results are also significant because LRW could be used in the future as a starting compound for the design of new and more potent antihypertensive compounds such as peptidomimetics. Each result is represented by the mean AE standard deviation from two determinations. Ã p < 0:05, ÃÃ p < 0:01 when compared with the control value in the absence of LRW at the same incubation time.
